Narrative review highlights association between abnormal bilirubin and Parkinson's disease motor outcomes

This narrative review evaluates the potential link between bilirubin metabolism and Parkinson's disease pathogenesis. The scope encompasses patients with Parkinson's disease, focusing specifically on the presence of abnormal bilirubin levels as an exposure variable within the context of neurological health.

The authors synthesize existing literature to note that abnormal bilirubin levels correlate with Parkinson's disease severity and motor outcomes. The review discusses the dual role of bilirubin in disease progression and potential therapeutic applications. No specific effect sizes or confidence intervals were reported in the source material, limiting quantitative interpretation.

A critical limitation noted is the inability to infer causation from the observed correlations. The review does not provide data on study populations, sample sizes, or follow-up durations. Additionally, comparators and primary outcomes were not reported in the available text, preventing direct clinical comparisons.

Clinical application remains uncertain due to the lack of reported practice relevance and safety data. Adverse events and discontinuations were not reported, and tolerability information is absent. Clinicians should interpret these findings as observational associations rather than established treatment targets or definitive biomarkers for management.